

Reimbursement Policy

Pathogen Panel Testing

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Infectious diseases can be caused by a wide range of pathogens. Conventional diagnostic methods like culture, microscopy with or without stains and immunofluorescence, and immunoassay often lack sensitivity and specificity and have long turnaround times. Panels for pathogens using multiplex amplified probe techniques and multiplex reverse transcription can detect and identify multiple pathogens in one test using a single sample.¹

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

This policy is specific to testing in the outpatient setting. Criteria below do not apply to testing allowances in situations other than the outpatient setting.

- 1) For individuals with persistent diarrhea or diarrhea with signs or risk factors for severe disease (i.e., fever, bloody diarrhea, dysentery, dehydration, severe abdominal pain), multiplex PCR-based panel testing (up to **11** gastrointestinal pathogens [GIPs]) no more often than once every 7 days **MEETS COVERAGE CRITERIA**.
- 2) For individuals who are displaying signs and symptoms of a respiratory tract infection (see Note 1), panel testing of up to **5** respiratory pathogens (antigen panel testing or multiplex PCR-based panel testing) **MEETS COVERAGE CRITERIA**.
- 3) For individuals who are immunocompromised **and** who are displaying signs and symptoms of a respiratory tract infection (see Note 1), multiplex PCR-based panel testing of up to 25 respiratory pathogens **MEETS COVERAGE CRITERIA**.
- 4) Multiplex PCR-based panel testing of **12 or more** GIPs **DOES NOT MEET COVERAGE CRITERIA**.

Reimbursement Policy

- 5) For all situations not described above, antigen panel testing or multiplex PCR-based panel testing of **6 or more** respiratory pathogens **DOES NOT MEET COVERAGE CRITERIA**.
- 6) Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) **DOES NOT MEET COVERAGE CRITERIA**.
- 7) Molecular detection-based panel testing of pathogens in the blood **DOES NOT MEET COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 8) Molecular detection-based panel testing of urine pathogens for the diagnosis of urinary tract infections (e.g., GENETWORx Molecular PCR UTI Test) **DOES NOT MEET COVERAGE CRITERIA**.
- 9) Molecular-based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing) **DOES NOT MEET COVERAGE CRITERIA**.
- 10) Molecular-based panel testing for general screening of microorganisms (e.g., MicroGenDX qPCR+ NGS) **DOES NOT MEET COVERAGE CRITERIA**.

NOTES:

Note 1: Signs and symptoms of a respiratory tract infection include fever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia, headaches, myalgia, diarrhea, and weakness.² Additional signs and symptoms of a respiratory tract infection may be seen in individuals who are less than 18 years of age. These include irritability, decreased activity, nausea, rash, stomach pain, ear tugging/otalgia, vomiting after coughing, tachypnea, chest retractions/nasal flaring, grunting, wheezing, crackles, dehydration, cyanosis, apnea episodes, drooling, or refusal to eat. For infants, non-specific signs such as poor feeding, lethargy, and fussiness may present over clear localizing symptoms.³⁻⁷

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare->

Reimbursement Policy

[coverage-database/search.aspx](#). For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

There are numerous FDA-approved pathogen panels. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
87154	Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets
87428	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
87483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen (e.g., Neisseria meningitidis, Streptococcus pneumoniae, Listeria, Haemophilus influenzae, E. coli, Streptococcus agalactiae, enterovirus, human parechovirus, herpes simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus, Cryptococcus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets

Reimbursement Policy

CPT	Code Description
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
0068U	Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species Proprietary test: MycoDART-PCR™ dual amplification real time PCR panel for 6 Candida species Lab/Manufacturer: RealTime Laboratories, Inc/MycoDART, Inc
0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility Proprietary test: Accelerate PhenoTest™ BC kit Lab/Manufacturer: Accelerate Diagnostics, Inc.
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species Proprietary test: MYCODART Dual Amplification Real Time PCR Panel for 4 Aspergillus species Lab/Manufacturer: RealTime Laboratories/MycoDART, Inc
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene Proprietary test: MicroGenDX qPCR & NGS For Infection Lab/Manufacturer: MicroGenDX

Reimbursement Policy

CPT	Code Description
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected Proprietary test: ePlex Respiratory Pathogen Panel Lab/Manufacturer: GenMark Diagnostics, Inc
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected Proprietary test: ePlex® BCID Fungal Pathogens Panel Lab/Manufacturer: GenMark Diagnostics, Inc
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected Proprietary test: ePlex® BCID Gram-Positive Panel Lab/Manufacturer: GenMark Diagnostics, Inc
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected Proprietary test: ePlex® BCID Gram-Negative Panel Lab/Manufacturer: GenMark Diagnostics, Inc
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens Proprietary test: Karius® Test Lab/Manufacturer: Karius Inc
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected Proprietary test: BioFire® Respiratory Panel 2.1 (RP2.1) Lab/Manufacturer: BioFire® Diagnostics

Reimbursement Policy

CPT	Code Description
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected Proprietary test: QIAstat-Dx Respiratory SARS CoV-2 Panel Lab/Manufacturer: QIAGEN GmbH
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected Proprietary test: ePlex® Respiratory Pathogen Panel 2 Lab/Manufacturer: GenMark Diagnostics
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique Proprietary test: Bridge Urinary Tract Infection Detection and Resistance Test Lab/Manufacturer: Bridge Diagnostics
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi Proprietary test: Johns Hopkins Metagenomic Next-Generation Sequencing Assay for Infectious Disease Diagnostics Lab/Manufacturer: Johns Hopkins Medical Microbiology Laboratory
0441U	Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index Proprietary test: IntelliSep® test Lab/Manufacturer: Cytovale®
0442U	Infectious disease (respiratory infection), myxovirus resistance protein a (mxr) and c-reactive protein (crp), fingerstick whole blood specimen, each biomarker reported as present or absent Proprietary test: FebriDx® Bacterial/NonBacterial Point-of Care Assay Lab/Manufacturer: Lumos Diagnostics, LLC, Lumos Diagnostics, LLC

Reimbursement Policy

CPT	Code Description
0480U	Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification Proprietary test: Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF) Lab/Manufacturer: Mayo Clinic, Laboratory Developed Test
0504U	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism Proprietary test: Urinary Tract Infection Testing Lab/Manufacturer: NxGen MDx LLC
0528U	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria Proprietary Test: BIOFIRE® FILMARRAY® Pneumonia (PN) Panel Lab/Manufacturer: bioMérieux, bioMérieux
0531U	Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), nextgeneration sequencing, plasma Proprietary test: NeXGen™ Fungal/AFB NGS Assay Lab/Manufacturer: Eurofins Viracor, LLC
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected Proprietary test: HealthTrackRx Bronchitis, HealthTrackRx Lab/Manufacturer: Thermo Fisher Scientific
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative Proprietary test: BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Respiratory Menu Lab/Manufacturer: bioMérieux

Reimbursement Policy

CPT	Code Description
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative Proprietary test: BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel – Sore Throat Menu, Lab/Manufacturer: bioMérieux
0590U	Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism Proprietary test: BIOTIA-IDTM Urine NGS Assay Lab/Manufacturer: Biotia Inc
0593U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected Proprietary test: Taq Array Card Urinary Tract Infection PCR Panel Lab/Manufacturer: SoftCell Laboratories LLC, Doc Lab Inc

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Palavecino E. One Sample, Multiple Results The Use of Multiplex PCR for Diagnosis of Infectious Syndromes. Webpage. *Clinical Laboratory News*. 2019;2018(11/1)doi:10.1016/j.idc.2019.10.006
2. CDC. About Respiratory Illnesses. Updated July 19, 2024. <https://www.cdc.gov/respiratory-viruses/about/index.html>
3. AAP. Respiratory Syncytial Virus. *Red Book: 2021–2024 Report of the Committee on Infectious Diseases*. 2021:0. doi:10.1542/9781610025782-S3_114
4. CDC. About Rhinoviruses. Updated April 24, 2024. <https://www.cdc.gov/rhinoviruses/about/index.html>
5. CDC. About Strep Throat. Updated March 1, 2024. <https://www.cdc.gov/group-a-strep/about/strep-throat.html>
6. CDC. RSV in Infants and Young Children. Updated August 30, 2024. <https://www.cdc.gov/rsv/infants-young-children/index.html>
7. CDC. Respiratory Viruses and Young Children. Updated September 26, 2024. <https://www.cdc.gov/respiratory-viruses/risk-factors/young-children.html>

Reimbursement Policy

8. CMS. Local Coverage Determination (LCD): Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification Tests (NAATs) (L37766). <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37766>
9. Leber W, Lammel O, Siebenhofer A, Redlberger-Fritz M, Panovska-Griffiths J, Czypionka T. Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2). *eClinicalMedicine*. 2021;38doi:10.1016/j.eclinm.2021.101011
10. WHO. Diarrhoeal disease. <https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease>
11. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States--unspecified agents. *Emerging infectious diseases*. Jan 2011;17(1):16-22. doi:10.3201/eid1701.091101p2
12. Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. *The American journal of gastroenterology*. May 2016;111(5):602-22. doi:10.1038/ajg.2016.126
13. Scallan Walter EJ CZ, Tierney R, Griffin PM, Hoekstra RM, Payne DC, et al. Foodborne Illness Acquired in the United States—Major Pathogens, 2019. *Emerging Infectious Diseases*. 2025;31(4):669-677doi:10.3201/eid3104.240913
14. Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). *Clin Infect Dis*. Mar 5 2024;doi:10.1093/cid/ciae104
15. Humphries RM, Linscott AJ. Laboratory diagnosis of bacterial gastroenteritis. *Clin Microbiol Rev*. Jan 2015;28(1):3-31. doi:10.1128/cmr.00073-14
16. Zhang H, Morrison S, Tang YW. Multiplex polymerase chain reaction tests for detection of pathogens associated with gastroenteritis. *Clinics in laboratory medicine*. Jun 2015;35(2):461-86. doi:10.1016/j.cll.2015.02.006
17. Fernandez-Soto P, Sanchez-Hernandez A, Gandasegui J, et al. Strong-LAMP: A LAMP Assay for Strongyloides spp. Detection in Stool and Urine Samples. Towards the Diagnosis of Human Strongyloidiasis Starting from a Rodent Model. *PLoS Negl Trop Dis*. Jul 2016;10(7):e0004836. doi:10.1371/journal.pntd.0004836
18. La Hoz RM, Morris MI. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. Sep 2019;33(9):e13618. doi:10.1111/ctr.13618
19. BioFire. The BioFire® FilmArray® Gastrointestinal (GI) Panel. <https://www.biofire.com/products/the-filmarray-panels/filmarraygi/>
20. Luminex. xTAG® Gastrointestinal Pathogen Panel (GPP). <https://www.luminexcorp.com/gastrointestinal-pathogen-panel/>
21. BioCode. FDA-Cleared Gastrointestinal Pathogen Panel (GPP). https://www.apbiocode.com/gi_panel.htm

Reimbursement Policy

22. Thomas M, Bomar PA. Upper Respiratory Tract Infection. *StatPearls*. StatPearls Publishing LLC.; 2023. <https://pubmed.ncbi.nlm.nih.gov/30422556/>
23. Hansen LS, Lykkegaard J, Thomsen JL, Hansen MP. Acute lower respiratory tract infections: Symptoms, findings and management in Danish general practice. *Eur J Gen Pract*. Dec 2020;26(1):14-20. doi:10.1080/13814788.2019.1674279
24. Ginocchio CC. Detection of respiratory viruses using non-molecular based methods. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. Nov 2007;40 Suppl 1:S11-4. doi:10.1016/s1386-6532(07)70004-5
25. Bonnin P, Miszczak F, Kin N, et al. Study and interest of cellular load in respiratory samples for the optimization of molecular virological diagnosis in clinical practice. journal article. August 09 2016;16(1):384. doi:10.1186/s12879-016-1730-9
26. Pammi M. Neonatal bacterial sepsis: Clinical features and diagnosis in neonates born at less than 35 weeks gestation. Updated November 11, 2024. <https://www.uptodate.com/contents/neonatal-bacterial-sepsis-clinical-features-and-diagnosis-in-neonates-born-at-less-than-35-weeks-gestation>
27. Caliendo AM. Multiplex PCR and Emerging Technologies for the Detection of Respiratory Pathogens. *Clinical Infectious Diseases*. 2011;52(suppl_4):S326-S330. doi:10.1093/cid/cir047
28. Yan Y, Zhang S, Tang YW. Molecular assays for the detection and characterization of respiratory viruses. *Seminars in respiratory and critical care medicine*. Aug 2011;32(4):512-26. doi:10.1055/s-0031-1283288
29. Lewinski MA, Alby K, Babady NE, et al. Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology. *The Journal of Molecular Diagnostics*. 2023;25(12):857-875. doi:10.1016/j.jmoldx.2023.08.005
30. Baghdadi JD, Tung CC, Johnson JK, Morgan DJ, Harris AD. Changes in use of multiplex respiratory panel testing during the COVID-19 pandemic. *Infect Control Hosp Epidemiol*. Oct 10 2024;1-6. doi:10.1017/ice.2024.163
31. Brendish NJ, Poole S, Naidu VV, et al. Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. *The Lancet Respiratory Medicine*. 2020;8(12):1192-1200. doi:10.1016/S2213-2600(20)30454-9
32. ASM. Making Sense of Respiratory Viral Panel Results. <https://asm.org/articles/2020/march/making-sense-of-respiratory-viral-panel-results>
33. BioFire. The BioFire® FilmArray® Respiratory 2.1 (RP2.1) Panel. <https://www.biofire.com/products/the-filmarray-panels/filmarrayrp/>
34. GenMark. Respiratory Pathogen (RP) Panel and NEW Respiratory Pathogen Panel 2 (RP2). <https://www.genmarkdx.com/solutions/panels/eplex-panels/respiratory-pathogen-panel/>
35. BioCode. FDA-Cleared Respiratory Pathogen Panel (RPP). https://apbiocode.com/rpp_panel.htm

Reimbursement Policy

36. Diasorin. NxTAG® Respiratory Pathogen Panel v2. Updated 2025.
<https://us.diasorin.com/en/molecular-diagnostics/kits-reagents/nxtag-respiratory-pathogen-panel-V2>
37. QIAGEN. QIAstat-Dx Respiratory SARS-CoV-2 Panel.
<https://www.qiagen.com/us/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-eua-us/>
38. Visseaux B, Le Hingrat Q, Collin G, et al. Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. *Journal of Clinical Microbiology*. 2020;58(8):e00630-20. doi:10.1128/JCM.00630-20
39. Veritor B. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B.
<https://bdveritor.bd.com/en-us/products/cov2-flu-a-b>
40. Healthcare O. QuickFinder™ COVID-19 / Flu Antigen Self Test.
https://www.osanghc.com/en/products_en/immunodiagnosis/#
41. QuidelOrtho. QuickVue® COVID-19 Test.
<https://www.quidelortho.com/global/en/consumers/quickvue-otc>
42. Dando SJ, Mackay-Sim A, Norton R, et al. Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. *Clin Microbiol Rev*. Oct 2014;27(4):691-726. doi:10.1128/cmr.00118-13
43. CDC. About Bacterial Meningitis. Updated January 9, 2024.
<https://www.cdc.gov/meningitis/about/bacterial-meningitis.html>
44. CDC. About Fungal Meningitis. Updated January 7, 2025.
<https://www.cdc.gov/meningitis/about/fungal-meningitis.html>
45. CDC. About Meningococcal Disease. Updated February 1, 2024.
<https://www.cdc.gov/meningococcal/about/index.html>
46. Petti CA, Polage CR. Molecular diagnosis of central nervous system infections. Updated July 31, 2023. <https://www.uptodate.com/contents/molecular-diagnosis-of-central-nervous-system-infections>
47. BioFire. The BioFire® FilmArray® Meningitis/Encephalitis (ME) Panel.
<https://www.biofiredx.com/products/the-filmarray-panels/filmarrayme/>
48. CDC. About Sepsis. Updated March 8, 2024. <https://www.cdc.gov/sepsis/about/>
49. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. *SAGE Open Med*. 2019;7:2050312119835043. doi:10.1177/2050312119835043
50. Liesenfeld O, Lehman L, Hunfeld KP, Kost G. Molecular diagnosis of sepsis: New aspects and recent developments. *European journal of microbiology & immunology*. 2014;4(1):1-25. doi:10.1556/EuJMI.4.2014.1.1
51. Lamy B, Sundqvist M, Idelevich EA. Bloodstream infections - Standard and progress in pathogen diagnostics. *Clin Microbiol Infect*. Feb 2020;26(2):142-150. doi:10.1016/j.cmi.2019.11.017

Reimbursement Policy

52. Banerjee R, Teng CB, Cunningham SA, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. *Clin Infect Dis*. Oct 1 2015;61(7):1071-80. doi:10.1093/cid/civ447
53. T2Biosystems. T2Bacteria Panel. <https://www.t2biosystems.com/products-technology/t2bacteria-panel/>
54. Diagnostics R. cobas® eplex Blood Culture Identification Panels. <https://diagnostics.roche.com/us/en/products/params/eplex-bcid-panels.html>
55. BioFire. The BioFire® FilmArray® Blood Culture Identification (BCID) Panel. <https://www.biofire.com/products/the-filmarray-panels/filmarraybcid/>
56. Bonkat G, Bartoletti R, Bruyere F, et al. European Association of Urology (EAU) Guidelines on Urological Infections. Updated March 2025. <http://uroweb.org/guideline/urological-infections/#3>
57. Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Updated February 28, 2025. <https://www.uptodate.com/contents/acute-complicated-urinary-tract-infection-including-pyelonephritis-in-adults>
58. Meyrier A. Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults. Updated February 28, 2025. <https://www.uptodate.com/contents/sampling-and-evaluation-of-voided-urine-in-the-diagnosis-of-urinary-tract-infection-in-adults>
59. MircoGenDX. UroKEY. <https://patients.microgen.com/products/urokey>
60. Pathnostics. Guidance UTI. <https://pathnostics.com/tests/guidance-uti/#1647110828433-7f31d2bd-54d7>
61. Armstrong D, Meyr A. Principles of acute wound management. Updated May 29, 2025. <https://www.uptodate.com/contents/principles-of-acute-wound-management>
62. GenetWorx. Wounds Pathogen Panel. <https://www.genetworx.com/services/wound-pathogen-panel>
63. Viracor. Skin and Soft Tissue Infection Panel TEM-PCR™. <https://www.eurofins-viracor.com/test-menu/220798p-skin-and-soft-tissue-infection-panel-tem-pcr/>
64. MicroGenDX. Wound Care <https://microgen.com/wound-care/>
65. Buss SN, Leber A, Chapin K, et al. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. *J Clin Microbiol*. Mar 2015;53(3):915-25. doi:10.1128/jcm.02674-14
66. Claas EC, Burnham CA, Mazzulli T, Templeton K, Topin F. Performance of the xTAG(R) gastrointestinal pathogen panel, a multiplex molecular assay for simultaneous detection of bacterial, viral, and parasitic causes of infectious gastroenteritis. *Journal of microbiology and biotechnology*. 2013;23(7):1041-5.
67. Onori M, Coltella L, Mancinelli L, et al. Evaluation of a multiplex PCR assay for simultaneous detection of bacterial and viral enteropathogens in stool samples of paediatric patients. *Diagnostic microbiology and infectious disease*. Jun 2014;79(2):149-54. doi:10.1016/j.diagmicrobio.2014.02.004

Reimbursement Policy

68. Humphrey JM, Ranbhise S, Ibrahim E, et al. Multiplex Polymerase Chain Reaction for Detection of Gastrointestinal Pathogens in Migrant Workers in Qatar. 2016;95(6):1330-1337. doi:10.4269/ajtmh.16-0464
69. Liu J, Kabir F, Manneh J, et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. *The Lancet Infectious diseases*. Aug 2014;14(8):716-724. doi:10.1016/s1473-3099(14)70808-4
70. Operario DJ, Houpt E. Defining the causes of diarrhea: novel approaches. *Current opinion in infectious diseases*. Oct 2011;24(5):464-71. doi:10.1097/QCO.0b013e32834aa13a
71. Couturier MR, Lee B, Zelyas N, Chui L. Shiga-toxigenic Escherichia coli detection in stool samples screened for viral gastroenteritis in Alberta, Canada. *J Clin Microbiol*. Feb 2011;49(2):574-8. doi:10.1128/jcm.01693-10
72. Xie J, Kim K, Berenger BM, et al. Comparison of a Rapid Multiplex Gastrointestinal Panel with Standard Laboratory Testing in the Management of Children with Hematochezia in a Pediatric Emergency Department: Randomized Controlled Trial. *Microbiol Spectr*. Jun 15 2023;11(3):e0026823. doi:10.1128/spectrum.00268-23
73. Cybulski RJ, Jr., Bateman AC, Bourassa L, et al. Clinical Impact of a Multiplex Gastrointestinal Polymerase Chain Reaction Panel in Patients With Acute Gastroenteritis. *Clin Infect Dis*. Nov 13 2018;67(11):1688-1696. doi:10.1093/cid/ciy357
74. Beal SG, Tremblay EE, Toffel S, Velez L, Rand KH. A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs. *J Clin Microbiol*. Jan 2018;56(1)doi:10.1128/jcm.01457-17
75. Zhan Z, Guo J, Xiao Y, et al. Comparison of BioFire FilmArray gastrointestinal panel versus Luminex xTAG Gastrointestinal Pathogen Panel (xTAG GPP) for diarrheal pathogen detection in China. *Int J Infect Dis*. Oct 2020;99:414-420. doi:10.1016/j.ijid.2020.08.020
76. van Asten SAV, Boers SA, de Groot JDF, Schuurman R, Claas ECJ. Evaluation of the Genmark ePlex® and QIAstat-Dx® respiratory pathogen panels in detecting bacterial targets in lower respiratory tract specimens. *BMC Microbiol*. Aug 26 2021;21(1):236. doi:10.1186/s12866-021-02289-w
77. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. 2018;doi:10.1093/cid/ciy866
78. Mormeneo Bayo S, López González E, Bellés Bellés A, et al. Detection and pathological role of intestinal protozoa in children. *Parasitol Int*. Jun 2022;88:102558. doi:10.1016/j.parint.2022.102558
79. Ward C, Stocker K, Begum J, Wade P, Ebrahimsa U, Goldenberg SD. Performance evaluation of the Verigene(R) (Nanosphere) and FilmArray(R) (BioFire(R)) molecular assays for identification of causative organisms in bacterial bloodstream infections. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. Mar 2015;34(3):487-96. doi:10.1007/s10096-014-2252-2

Reimbursement Policy

80. Chang S-S, Hsieh W-H, Liu T-S, et al. Multiplex PCR System for Rapid Detection of Pathogens in Patients with Presumed Sepsis – A Systemic Review and Meta-Analysis. *PLOS ONE*. 2013;8(5):e62323. doi:10.1371/journal.pone.0062323
81. Almonacid DE, Kraal L, Ossandon FJ, et al. 16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome. *PLOS ONE*. 2017;12(5):e0176555. doi:10.1371/journal.pone.0176555
82. Watts GS, Youens-Clark K, Slepian MJ, et al. 16S rRNA gene sequencing on a benchtop sequencer: accuracy for identification of clinically important bacteria. *Journal of applied microbiology*. 2017;123(6):1584-1596. doi:10.1111/jam.13590
83. V. Wintzingerode F, Göbel UB, Stackebrandt E. Determination of microbial diversity in environmental samples: pitfalls of PCR-based rRNA analysis. 1997;21(3):213-229. doi:doi:10.1111/j.1574-6976.1997.tb00351.x
84. Medical Diagnostics. One Vial, Multiple Pathogens. <https://www.mdlab.com/>
85. McCarty TP, Cumagun P, Meeder J, et al. Test Performance and Potential Clinical Utility of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel. *Microbiol Spectr*. Feb 14 2023;11(1):e0409222. doi:10.1128/spectrum.04092-22
86. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *The American journal of gastroenterology*. Apr 2013;108(4):478-98; quiz 499. doi:10.1038/ajg.2013.4
87. ACG. ACG updates clinical guidelines on prevention, diagnosis, treatment of *C. difficile* infection. ACP Gastroenterology Monthly Newsletter: American College of Gastroenterology; 2021.
88. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of *Clostridioides difficile* Infections. *Official journal of the American College of Gastroenterology | ACG*. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278
89. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. *Clin Infect Dis*. Nov 29 2017;65(12):1963-1973. doi:10.1093/cid/cix959
90. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. Mar 19 2018;66(7):e1-e48. doi:10.1093/cid/cix1085
91. Hanson KE, Azar MM, Banerjee R, et al. Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA's Diagnostics Committee. *Clin Infect Dis*. Dec 17 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508
92. Hayden M, Hanson K, Englund J, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Infectious Diseases Society of America. Updated September 6, 2023. <https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/#Recommendation8:NAATinAsymptomaticIndividualsbeforeHospitalAdmission>

Reimbursement Policy

93. American Society for Microbiology. MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels (DL37301). <https://www.amp.org/AMP/assets/File/position-statements/2017/JointCommentLettertoNoridioanJEforMultiplexViralPanelTests-Respiratory-DL37301.pdf>
94. Schultz G, Bjarnsholt T, James GA, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. *Wound Repair Regen*. Sep 2017;25(5):744-757. doi:10.1111/wrr.12590
95. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Critical care medicine*. Mar 2017;45(3):486-552. doi:10.1097/ccm.0000000000002255
96. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. *Pediatr Crit Care Med*. Feb 2020;21(2):e52-e106. doi:10.1097/pcc.0000000000002198
97. O'Grady NP, Alexander E, Alhazzani W, et al. Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU. *Critical care medicine*. 2023;51(11):1570-1586. doi:10.1097/ccm.0000000000006022
98. Hill AT, Gold PM, El Solh AA, Metlay JP, Ireland B, Irwin RS. Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report. *Chest*. Jan 2019;155(1):155-167. doi:10.1016/j.chest.2018.09.016
99. CDC. Clinical Testing and Diagnosis for CDI. Updated March 6, 2024. <https://www.cdc.gov/c-diff/hcp/diagnosis-testing/index.html>
100. CDC. Clinical Guidance for Patients with Acute Respiratory Illness Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co-Circulating. Updated December 6, 2023. <https://www.cdc.gov/flu/hcp/clinical-guidance/testing-guidance-for-clinicians-hospitalized.html>
101. ASCP. ASCP Expands List of Commonly Used Tests Physicians and Patients Should Question. <https://www.ascp.org/news/news-details/2019/09/10/ascp-expands-list-of-commonly-used-tests-physicians-and-patients-should-question>

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Off-cycle Review, no updates outside of the coverage criteria: New CC3: “3) For individuals who are immunocompromised and who are displaying signs and symptoms of a respiratory tract infection (see Note 1), multiplex PCR-based panel testing of up to 25 respiratory pathogens MEETS COVERAGE CRITERIA.”

Reimbursement Policy

	Former CC4, now CC5, added “For all situations not described above,”, now reads: “5) For all situations not described above, antigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens DOES NOT MEET COVERAGE CRITERIA.” Added CPT code 0590U, 0593U (effective date 10/1/2025)
--	---